Business Context and Reporting Period
Company: Mangoceuticals, Inc. (MGRX)
Filing Type: Form 8-K (Current Report)
Date of Report: January 27, 2025 (Events reported through January 30, 2025)
Context: The filing discloses the entry into several material definitive agreements, including debt amendments, related-party service contracts, and a new distribution partnership. The company is an emerging growth company.
Key Financial Metrics and Agreements
This filing does not contain standard financial statements (revenue, profit, cash flow). Key financial terms disclosed include:
- Debt Obligation: $500,000 owed to MAAB Global Ltd. (purchased from Barstool Sports, Inc.).
- Debt Conversion Terms: Convertible to common stock at $1.50 per share (maximum 333,334 shares).
- Related-Party Compensation:
- Epiq Scripts, LLC: Assignment of service agreements to subsidiary Mango & Peaches Corp. (M&P). CEO Jacob Cohen receives 1,700,000 M&P shares (25.4% ownership) and 100 Series A Super Majority Voting Preferred Shares (51% voting control).
- LT Global Practice Management: Owned by CEO's wife. Virtual professionals billed at $1,800 to $3,500 per month per professional.
- Equity Compensation (Distribution): 650,000 restricted common shares issued to Propre Energie Inc. plus 1% of gross sales revenue.
Material Changes and New Agreements
The following material changes occurred in late January 2025:
- Debt Restructuring: Amended payment plan with MAAB Global to allow debt-to-equity conversion at any time.
- Related-Party Transactions:
- Assigned existing Master Services and Consulting agreements with Epiq Scripts (51% owned by CEO) to the subsidiary M&P.
- Entered a service agreement with LT Global (owned by CEO's wife) for virtual staffing.
Strategic Partnership: Entered a Master Distribution Agreement with Propre Energie Inc. to license "Dermytol" brand IP for plant-based skin formulations.
Outlook, Risks, and Contingencies
- Dilution Risk: Potential issuance of up to 333,334 shares upon full debt conversion and 650,000 shares for the Propre distribution deal.
- Related-Party Risks: Significant concentration of control and financial interest in agreements with entities owned by the CEO and his spouse. The CEO holds 51% voting control of the subsidiary M&P.
- Revenue Contingency: Future revenue from the Propre agreement is contingent on gross sales, with a 1% royalty obligation.
- Termination Clauses: The Propre agreement allows termination if the company sells substantially all assets or becomes insolvent.
Investor Verification Checklist
- Verify the exact number of shares outstanding to assess the dilution impact of the 333,334 convertible shares and 650,000 Propre shares.
- Review the full text of Exhibits 10.4, 10.5, and 10.6 to understand the specific scope of services and total potential costs for the related-party agreements with Epiq Scripts and LT Global.
- Confirm the current status of the $500,000 debt and whether MAAB Global has elected to convert to equity.
- Assess the financial health of the subsidiary Mango & Peaches Corp. given the CEO's majority voting control.